1
Thorsteinn Loftsson, Einar Stefánsson: Cyclodextrin nanotechnology for ophthalmic drug delivery. Oculis ehf, Buchanan Ingersoll & Rooney PC, February 22, 2011: US07893040 (18 worldwide citation)

The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), ...


2
Loftsson Thorsteinn, Stefansson Einar: Cyclodextrin nanotechnology for ophthalmic drug delivery. Oculis Ehf, Loftsson Thorsteinn, Stefansson Einar, HEDLEY Nicholas James Matthew, February 1, 2007: WO/2007/012974 (4 worldwide citation)

The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin com&rgr;lex( ...


3
Thorsteinn Loftsson, Einar Stefansson: Cyclodextrin nanotechnology for ophthalmic drug delivery. Oculis EHF, Dentons US, April 7, 2015: US08999953 (1 worldwide citation)

The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), ...


4
Thorsteinn Loftsson, Einar Stefansson: Cyclodextrin nanotechnology for ophthalmic drug delivery. Oculis EHF, Dentons US, January 21, 2014: US08633172 (1 worldwide citation)

The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), ...


5
Loftsson Thorsteinn, Stefansson Einar: Cyclodextrin nanotechnology for ophthalmic drug delivery. Oculis Ehf, April 16, 2008: EP1909755-A2

The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin com?lex(es), ...


6
Thorsteinn Loftsson, Einar Stefansson: Cyclodextrin nanotechnology for ophthalmic drug delivery. Oculis Ehf, Buchanan Ingersoll & Rooney PC, January 25, 2007: US20070020336-A1

The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), ...


7
Thorsteinn Loftsson, Einar Stefansson: Cyclodextrin nanotechnology for ophthalmic drug delivery. Oculis Ehf, February 2, 2012: US20120028944-A1

The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), ...


8
CYCLODEXTRIN NANOTECHNOLOGY FOR OPHTHALMIC DRUG DELIVERY. OCULIS EHF, June 6, 2013: US20130142791-A1

The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), ...


9
CYCLODEXTRIN NANOTECHNOLOGY FOR OPHTHALMIC DRUG DELIVERY. OCULIS EHF, July 3, 2014: US20140186443-A1

The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), ...